Midatech Pharma (NASDAQ: MTP) is one of 531 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Midatech Pharma to related companies based on the strength of its institutional ownership, dividends, earnings, analyst recommendations, profitability, risk and valuation.

Volatility and Risk

Midatech Pharma has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Comparatively, Midatech Pharma’s rivals have a beta of 1.16, suggesting that their average share price is 16% more volatile than the S&P 500.


This table compares Midatech Pharma and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Midatech Pharma N/A N/A N/A
Midatech Pharma Competitors -1,934.28% -92.21% -26.20%

Valuation & Earnings

This table compares Midatech Pharma and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Midatech Pharma $9.79 million -$20.70 million -0.30
Midatech Pharma Competitors $2.18 billion $164.12 million -1.82

Midatech Pharma’s rivals have higher revenue and earnings than Midatech Pharma. Midatech Pharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Midatech Pharma and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Midatech Pharma 0 0 0 0 N/A
Midatech Pharma Competitors 3890 11291 25551 854 2.56

As a group, “Pharmaceutical preparations” companies have a potential upside of 69.27%. Given Midatech Pharma’s rivals higher possible upside, analysts plainly believe Midatech Pharma has less favorable growth aspects than its rivals.

Insider and Institutional Ownership

0.3% of Midatech Pharma shares are owned by institutional investors. Comparatively, 46.3% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 15.3% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.


Midatech Pharma rivals beat Midatech Pharma on 5 of the 9 factors compared.

Midatech Pharma Company Profile

Midatech Pharma PLC, a specialty pharmaceutical company, focuses on developing and commercializing products in oncology and immunotherapy in the United States and the United Kingdom. The company operates through two segments, Pipeline Research and Development; and Commercial. Its products include Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; Gelclair, an oral gel barrier device indicated for the management and relief of pain due to oral mucositis; Oravig, an orally dissolving buccal tablet for oral thrush; and Soltamox, an oral liquid solution of tamoxifen citrate, for the treatment and prevention of breast cancer. Midatech Pharma PLC is collaborating with universities and pharmaceutical companies to develop its platform technologies into a range of products. Midatech Pharma PLC was founded in 2000 and is headquartered in Abingdon, the United Kingdom.

Receive News & Ratings for Midatech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.